What's Going On With CRISPR Therapeutics Stock?
Portfolio Pulse from Erica Kollmann
CRISPR Therapeutics AG (NASDAQ:CRSP) stock is trading higher despite Morgan Stanley maintaining an Underweight rating and lowering the price target from $43 to $42. RBC Capital and Needham also lowered their price targets, but Needham maintains a Buy rating. CRISPR reported Q3 losses better than expected, and the stock is trending among retail investors and short-sellers, with a high short interest of 17.72%.
November 13, 2023 | 5:45 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
CRISPR Therapeutics' stock is trading higher despite mixed analyst ratings and lowered price targets. The company beat Q3 loss estimates, which may contribute to positive sentiment. High short interest indicates potential volatility.
The stock is trading higher, which suggests that the market has already absorbed the news of the lowered price targets. The better-than-expected Q3 results may provide some positive sentiment, but the high short interest could lead to increased volatility in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100